A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe COPD

Trial Profile

A 12-week multi-center, randomized, double-blind, parallel-group study to assess the efficacy, safety and tolerability of the co-administration of NVA237 + indacaterol once daily vs. indacaterol once daily in patients with moderate to severe COPD

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Mar 2016

At a glance

  • Drugs Glycopyrrolate (Primary) ; Indacaterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms GLOW-6
  • Sponsors Novartis
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 23 May 2012 Planned end date changed from 12 Dec 2012 to 1 Jan 2013 as reported by ClinicalTrials.gov.
    • 23 May 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health; NCT01604278).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top